AKBA
NASDAQ · Biotechnology
Akebia Therapeutics Inc
$1.16
-0.02 (-1.69%)
Open$1.17
Previous Close$1.18
Day High$1.20
Day Low$1.13
52W High$4.08
52W Low$1.13
Volume—
Avg Volume3.41M
Market Cap309.83M
P/E Ratio—
EPS$-0.02
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+3,128.4% upside
Current
$1.16
$1.16
Target
$37.45
$37.45
$22.27
$37.45 avg
$46.32
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 243.23M | 261.20M | 65.59M |
| Net Income | -5,508,067 | -5,323,518 | -3,878,355 |
| Profit Margin | -2.3% | -2.2% | -5.9% |
| EBITDA | 21.08M | 21.50M | -4,128,349 |
| Free Cash Flow | — | — | -1,979,346 |
| Rev Growth | -6.9% | -6.9% | +11.6% |
| Debt/Equity | 5.94 | 5.94 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |